Clinical Trial Update: ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 3]

View source ↗

Summary

A Phase 3 trial compares ravulizumab (ALXN1210) with eculizumab in treatment-naïve adults with paroxysmal nocturnal hemoglobinuria; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Eculizumab (eculizumab)
• Ravulizumab (ravulizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | Status: COMPLETED | Results posted: 2019-02-12